Parameswaran Nair - Concepedia

Author

Parameswaran Nair

Also Known As

Mary Messieh, Nair, Parameswaran, P Nair, P. Nair, P.K. Nair, PARAMESWARAN K NAIR, Parameswaran K Nair, Parameswaran K. Nair, Parameswaran Nair, Parameswaran Nair1

413

Publications

18.2K

Citations

H-Index

111

Concepts

All Affiliations

McMaster University St. Joseph’s Healthcare Hamilton McGill University McGill University Health Centre Institute for Respiratory Health

About

Parameswaran Nair is an author at McMaster University specializing in medicine, asthma, and allergy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	50	4K
2	Allergy	20	32	2.1K
3	Health Sciences	5	5	191
4	Engineering	3	3	154
5	Public Health	1	1	15

Parameswaran Nair

130

Publications

12.3K

Citations

H-Index

Page 1

	Year	Citations
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia Parameswaran Nair, Márcia Margaret Menezes Pizzichini, Melanie Kjarsgaard, New England Journal of Medicine	2009	1.3K
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair, The Lancet AsthmaRheumatologyPlacebo-controlled Phase 3ImmunologyClinical Trials	2016	1.3K
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma Klaus F. Rabe, Parameswaran Nair, Guy Brusselle, New England Journal of Medicine	2018	1.1K
Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma Parameswaran Nair, Sally E. Wenzel, Klaus F. Rabe, New England Journal of Medicine	2017	1K
Reslizumab for Poorly Controlled, Eosinophilic Asthma Mario Castro, Sameer K. Mathur, Frederick E. Hargreave, American Journal of Respiratory and Critical Care Medicine	2011	715
Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia Steven G. Smith, Ruchong Chen, Melanie Kjarsgaard, Journal of Allergy and Clinical Immunology AsthmaGroup 2Severe AsthmaAllergyLung Inflammation	2015	445
Safety and efficacy of a <scp>CXCR</scp>2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial Parameswaran Nair, Mina Gaga, Khuder Alagha, Clinical & Experimental Allergy	2012	328
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial William W. Busse, Eugene R. Bleecker, J Mark FitzGerald, The Lancet Respiratory Medicine AsthmaRheumatologyExtension TrialAllergyAllergy Medicine	2018	298
EAACI Biologicals Guidelines—Recommendations for severe asthma Ioana Agache, Cezmi A. Akdiş, Mübeccel Akdiş, Allergy	2020	263
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial Paul M. O’Byrne, Hristo Metev, Margareta Puu, The Lancet Respiratory Medicine AsthmaCxcr2 AntagonistAllergyUncontrolled Persistent AsthmaClinical Trials	2016	256

Page 1